Sia Daneshmand, MD, joins the show to review 2 studies on

the use of erdafitinib for the treatment of non-muscle invasive bladder cancer,including the THOR-2 trial investigating erdafitinib versus intravesicalchemotherapy in patients who received BCG therapy and recurred with high-riskNMIBC. Dr. Daneshmand is the director of urologic oncology at the Keck Schoolof Medicine, University of Southern California, Los Angeles.